Research programme: oral film benign prostatic hyperplasia therapeutics - IntelGenxAlternative Names: INT0025; INT0025/2010; INT0026; INT0026/2011
Latest Information Update: 23 Dec 2013
Price : $50
At a glance
- Originator IntelGenx Corp.
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Benign prostatic hyperplasia
Most Recent Events
- 12 Dec 2013 No development reported - Preclinical for Benign prostatic hyperplasia in Canada (PO)